In addition, we also detected the expression level of PPARα, a key factor in lipid metabolism, which, in the model group, was significantly lower than that in the normal group and the SX-H/L group (P < 0.05, Figure 3(e)), suggesting that SX might alleviate dyslipidemia by upregulating the expression of PPARα to improve lipid metabolism. The gene discussed is PPARA; the disease is metabolic syndrome.